FibroTx, Leo Pharma Collaborate on Use of Biomarker Skin Test

NEW YORK (360Dx) – Leo Pharma said today that it has entered a collaboration with Estonia-based FibroTx to assess disease severity and monitor treatment effects in atopic dermatitis patients using a non-invasive skin test technology developed by FibroTx.

To read the full story….

…and receive Daily News bulletins.

Already have an account?

Source link

Leave a Reply

Your email address will not be published.